Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
PreDxion Bio
AddedFeb 15, 2024
UpdatedJun 18, 2026
PreDxion Bio

PreDxion Bio

Seed

PreDxion Bio: Rapid, scalable diagnostics for COVID-19 & more, leveraging novel sensor tech for at-home use.

HQ
Richmond, VA, US
Founded
2017
Accelerator
Y Combinator logoY CombinatorS17
Overview
Compare
Fundraising
Employees
Website

PreDxion Bio was founded with a mission to revolutionize rapid diagnostics for infectious diseases, starting with COVID-19. The company focuses on developing scalable, saliva-based antigen tests capable of detecting SARS-CoV-2 in asymptomatic and presymptomatic patients. Their innovative technology leverages semiconductor fabrication processes to produce tens of millions of tests daily, aiming to enhance public health response and enable widespread contact tracing. Originally rooted in critical care diagnostics, PreDxion Bio has expanded its vision to include at-home diagnostic solutions.

Key figures associated with PreDxion Bio include experts in biotechnology and semiconductor manufacturing. The company has garnered attention from notable investors in the healthcare and technology sectors. Among its significant achievements is the development of a rapid, near real-time cytokine detection technology, which laid the groundwork for their COVID-19 diagnostic solutions. PreDxion Bio's impact is marked by its potential to significantly improve disease detection and management, thereby contributing to better-informed public health decisions globally.

PreDxion Bio - Similar Companies

Proxim Diagnostics logo

Proxim Diagnostics

proximdx.com

Prompt Diagnostics logo

Prompt Diagnostics

prompt-dx.com

GeneCapture logo

GeneCapture

genecapture.com

AmplifiDx logo

AmplifiDx

amplifidx.com

PathogenDx logo

PathogenDx

pathogendx.com

DxDiscovery logo

DxDiscovery

dxdiscovery.com

OmniVis logo

OmniVis

IncellDx logo

IncellDx

healthbioai.com

Rapid Diagnostek logo

Rapid Diagnostek

Predictive Health Diagnostics Company logo

Predictive Health Diagnostics Company

Instadiagnostics logo

Instadiagnostics

Burst Diagnostics logo

Burst Diagnostics

burst-dx.com

AxonDx logo

AxonDx

axondx.com

Persperion Diagnostics logo

Persperion Diagnostics

persperiontech.com

PathoGene logo

PathoGene

PreDxion Bio - Quick Facts

Who are PreDxion Bio's competitors?

Companies similar to PreDxion Bio include Proxim Diagnostics, Prompt Diagnostics, GeneCapture and AmplifiDx.

When was PreDxion Bio founded?

PreDxion Bio was founded in 2017.

Where is PreDxion Bio's headquarters located?

PreDxion Bio's headquarters is located in Richmond, VA, US.

When was PreDxion Bio's last funding round?

PreDxion Bio's most recent funding round was for $6.3M (USD) in September 2020.

How much has PreDxion Bio raised to-date?

As of Sep 15, 2020, PreDxion Bio has raised a total of $6.4M (USD).

How many employees does PreDxion Bio have?

PreDxion Bio has 6 employees as of Aug 23, 2023.

PreDxion Bio - Classification

Industry
  • Hardware
Ownership
  • Private
  • Venture Capital
Technology
  • Analytics
Geographic Exposure
  • Americas
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
  • Government
Main Product
  • Diagnostics
  • Testing
Tags
  • Biotech
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 1 more industry code
NAICS
  • 623000Nursing and Residential Care Facilities